Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Taps Galapagos to Design siRNA-Based Cellular Assays for Target Validation

NEW YORK, July 6 (GenomeWeb News) - Galapagos said today that its Galadeno genomics division has entered into an agreement with Novartis Pharmaceuticals UK to design cellular assays using its SilenceSelect gene knock-down platform.

 

Galadeno will provide technology, reagents, and support to assist Novartis researchers in validating drug targets by analyzing protein function in human primary cells. Galadeno will receive payments related to the research services and its SilenceSelect technology.

 

Additional financial terms were not provided.

 

Galapagos said that Galadeno's SilenceSelect technology can knock down more than 4,000 human proteins by producing short interfering RNA in human cells.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.